CY1116847T1 - Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4 - Google Patents
Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4Info
- Publication number
- CY1116847T1 CY1116847T1 CY20151100681T CY151100681T CY1116847T1 CY 1116847 T1 CY1116847 T1 CY 1116847T1 CY 20151100681 T CY20151100681 T CY 20151100681T CY 151100681 T CY151100681 T CY 151100681T CY 1116847 T1 CY1116847 T1 CY 1116847T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fgf
- receptor
- receptor specific
- specific antagonists
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση έχει ως αντικείμενο της μόρια ειδικών ανταγωνιστών του υποδοχέα FGF-R4, τα οποία επιτρέπουν την αναστολή της δραστικότητας του υποδοχέα. Αυτοί οι ανταγωνιστές είναι, συγκεκριμένα, αντισώματα τα οποία κατευθύνονται ειδικότερα έναντι του υποδοχέα FGF-R4, επιτρέποντας την αναστολή της δραστικότητας του εν λόγω υποδοχέα. Η παρούσα εφεύρεση έχει επίσης ως αντικείμενο της τη θεραπευτική χρήση των εν λόγω αντισωμάτων, ιδιαίτερα δε στο πεδίο της αγγειογένεσης, και στην θεραπεία ορισμένων τύπων του καρκίνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0803888A FR2933702A1 (fr) | 2008-07-08 | 2008-07-08 | Antagonistes specifiques du recepteur fgf-r4 |
EP09784478.1A EP2315781B1 (fr) | 2008-07-08 | 2009-07-07 | Antagonistes specifiques du recepteur fgf-r4 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116847T1 true CY1116847T1 (el) | 2017-03-15 |
Family
ID=40626849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100681T CY1116847T1 (el) | 2008-07-08 | 2015-08-05 | Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4 |
Country Status (38)
Country | Link |
---|---|
US (1) | US20110150903A1 (el) |
EP (1) | EP2315781B1 (el) |
JP (2) | JP5726731B2 (el) |
KR (1) | KR20110028536A (el) |
CN (2) | CN103784954A (el) |
AR (1) | AR072699A1 (el) |
AU (1) | AU2009267834B2 (el) |
BR (1) | BRPI0915660A2 (el) |
CA (1) | CA2730300A1 (el) |
CL (1) | CL2011000047A1 (el) |
CO (1) | CO6440535A2 (el) |
CR (1) | CR11868A (el) |
CY (1) | CY1116847T1 (el) |
DK (1) | DK2315781T3 (el) |
DO (1) | DOP2011000005A (el) |
EA (2) | EA021580B1 (el) |
EC (1) | ECSP11010748A (el) |
ES (1) | ES2544761T3 (el) |
FR (1) | FR2933702A1 (el) |
HK (1) | HK1159133A1 (el) |
HN (1) | HN2011000074A (el) |
HR (1) | HRP20150836T1 (el) |
HU (1) | HUE027221T2 (el) |
IL (1) | IL210516A0 (el) |
MA (1) | MA32547B1 (el) |
MX (1) | MX2011000328A (el) |
NI (1) | NI201100012A (el) |
NZ (2) | NZ590860A (el) |
PE (1) | PE20110313A1 (el) |
PL (1) | PL2315781T3 (el) |
PT (1) | PT2315781E (el) |
SG (1) | SG10201403751XA (el) |
SI (1) | SI2315781T1 (el) |
TW (1) | TW201006492A (el) |
UA (1) | UA107782C2 (el) |
UY (1) | UY31970A (el) |
WO (1) | WO2010004204A2 (el) |
ZA (1) | ZA201100209B (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130079384A (ko) * | 2010-05-03 | 2013-07-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
CA2812389C (en) | 2010-09-27 | 2019-12-31 | John Kehoe | Antibodies binding human collagen ii |
BR112013024717A2 (pt) * | 2011-04-07 | 2017-08-08 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
WO2012177481A2 (en) * | 2011-06-24 | 2012-12-27 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
CN108888757A (zh) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
WO2014105849A1 (en) * | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Antibodies specific for fgfr4 and methods of use |
US9611319B2 (en) | 2013-03-12 | 2017-04-04 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |
US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
EA028819B1 (ru) | 2013-10-25 | 2018-01-31 | Новартис Аг | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 |
MX2016004822A (es) | 2013-10-28 | 2016-08-17 | Ngm Biopharmaceuticals Inc | Modelos de cancer y metodos asociados. |
TW201612518A (en) * | 2014-01-17 | 2016-04-01 | Sanofi Sa | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody |
MX2016009555A (es) | 2014-01-24 | 2016-12-08 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos para utilizarlas. |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
PL3170005T3 (pl) | 2014-07-18 | 2019-10-31 | Sanofi Sa | Sposób przewidywania wyniku leczenia afliberceptem u pacjenta podejrzewanego o chorobę nowotworową |
CN104177492B (zh) * | 2014-07-21 | 2017-02-22 | 暨南大学 | FGFR2c胞外段类似物及其编码基因与应用 |
TWI710575B (zh) * | 2014-08-11 | 2020-11-21 | 德商第一三共歐洲公司 | 人類抗-fgfr4抗體 |
EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
WO2016151499A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Formylated n-heterocyclic derivatives as fgfr4 inhibitors |
EP3095465A1 (en) | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
AU2016366521A1 (en) | 2015-12-11 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade |
JP6909220B2 (ja) | 2016-02-10 | 2021-07-28 | ダイイチサンキョウヨーロッパ ゲーエムベーハー | ヒト抗fgfr4抗体およびソラフェニブの組み合わせ |
MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
CN109922804B (zh) | 2016-11-02 | 2023-11-17 | 诺华股份有限公司 | Fgfr4抑制剂和胆汁酸螯合剂的组合 |
AU2017365367A1 (en) * | 2016-11-22 | 2019-05-30 | Merck Patent Gmbh | Monoclonal antibody directed to FGFR1 |
EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
CN109725159B (zh) * | 2018-12-28 | 2021-10-08 | 江苏众红生物工程创药研究院有限公司 | 人β2-微球蛋白的定量检测试纸卡与临床应用 |
JP2023511236A (ja) * | 2020-01-21 | 2023-03-16 | タボテック バイオセラピューティクス (ホンコン) リミテッド | IL-1β受容体シグナル伝達に干渉する剤 |
CA3176246A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
WO2022098662A2 (en) * | 2020-11-03 | 2022-05-12 | Twist Bioscience Corporation | Methods and compositions relating to chemokine receptor variants |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
AU767394C (en) * | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
DE602004032370D1 (de) * | 2003-10-16 | 2011-06-01 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
ES2582652T3 (es) * | 2006-02-10 | 2016-09-14 | Genentech, Inc. | Anticuerpos anti-FGF19 y métodos de uso de los mismos |
EP1918376A1 (en) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
WO2008052796A1 (en) * | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
CA2679268A1 (en) * | 2007-03-09 | 2008-09-18 | Novartis Ag | Treatment of melanoma |
-
2008
- 2008-07-08 FR FR0803888A patent/FR2933702A1/fr active Pending
-
2009
- 2009-07-07 DK DK09784478.1T patent/DK2315781T3/en active
- 2009-07-07 ES ES09784478.1T patent/ES2544761T3/es active Active
- 2009-07-07 SI SI200931242T patent/SI2315781T1/sl unknown
- 2009-07-07 CA CA2730300A patent/CA2730300A1/fr not_active Abandoned
- 2009-07-07 MX MX2011000328A patent/MX2011000328A/es active IP Right Grant
- 2009-07-07 SG SG10201403751XA patent/SG10201403751XA/en unknown
- 2009-07-07 AR ARP090102534A patent/AR072699A1/es unknown
- 2009-07-07 AU AU2009267834A patent/AU2009267834B2/en not_active Ceased
- 2009-07-07 UA UAA201101398A patent/UA107782C2/ru unknown
- 2009-07-07 JP JP2011517203A patent/JP5726731B2/ja not_active Expired - Fee Related
- 2009-07-07 EA EA201170155A patent/EA021580B1/ru not_active IP Right Cessation
- 2009-07-07 US US13/002,845 patent/US20110150903A1/en not_active Abandoned
- 2009-07-07 KR KR1020117002857A patent/KR20110028536A/ko not_active Application Discontinuation
- 2009-07-07 PT PT97844781T patent/PT2315781E/pt unknown
- 2009-07-07 EP EP09784478.1A patent/EP2315781B1/fr not_active Not-in-force
- 2009-07-07 HU HUE09784478A patent/HUE027221T2/en unknown
- 2009-07-07 NZ NZ590860A patent/NZ590860A/xx not_active IP Right Cessation
- 2009-07-07 EA EA201401107A patent/EA201401107A1/ru unknown
- 2009-07-07 PL PL09784478T patent/PL2315781T3/pl unknown
- 2009-07-07 WO PCT/FR2009/051343 patent/WO2010004204A2/fr active Application Filing
- 2009-07-07 CN CN201410084647.7A patent/CN103784954A/zh active Pending
- 2009-07-07 PE PE2011000015A patent/PE20110313A1/es not_active Application Discontinuation
- 2009-07-07 BR BRPI0915660A patent/BRPI0915660A2/pt not_active IP Right Cessation
- 2009-07-07 CN CN200980134842.3A patent/CN102149730B/zh not_active Expired - Fee Related
- 2009-07-07 NZ NZ602905A patent/NZ602905A/en not_active IP Right Cessation
- 2009-07-08 TW TW098123091A patent/TW201006492A/zh unknown
- 2009-07-08 UY UY0001031970A patent/UY31970A/es not_active Application Discontinuation
-
2010
- 2010-12-22 CR CR11868A patent/CR11868A/es not_active Application Discontinuation
-
2011
- 2011-01-06 IL IL210516A patent/IL210516A0/en unknown
- 2011-01-06 DO DO2011000005A patent/DOP2011000005A/es unknown
- 2011-01-07 NI NI201100012A patent/NI201100012A/es unknown
- 2011-01-07 HN HN2011000074A patent/HN2011000074A/es unknown
- 2011-01-07 CL CL2011000047A patent/CL2011000047A1/es unknown
- 2011-01-07 CO CO11001540A patent/CO6440535A2/es active IP Right Grant
- 2011-01-07 ZA ZA2011/00209A patent/ZA201100209B/en unknown
- 2011-01-07 EC EC2011010748A patent/ECSP11010748A/es unknown
- 2011-02-08 MA MA33595A patent/MA32547B1/fr unknown
- 2011-12-21 HK HK11113762.6A patent/HK1159133A1/xx not_active IP Right Cessation
-
2014
- 2014-10-17 JP JP2014212724A patent/JP2015057398A/ja active Pending
-
2015
- 2015-08-05 CY CY20151100681T patent/CY1116847T1/el unknown
- 2015-08-06 HR HRP20150836TT patent/HRP20150836T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116847T1 (el) | Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4 | |
CY1123883T1 (el) | Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1119901T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
CY1122466T1 (el) | Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης | |
CY1122651T1 (el) | Μεθοδοι και συνθεσεις για προσδιορισμο της αντιστασης εναντι θεραπειας υποδοχεα ανδρογονου | |
CY1122886T1 (el) | Αναστολεις βρωμοεπικρατειων | |
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
CY1125279T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
CY1118362T1 (el) | Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης | |
CY1114458T1 (el) | Πυρρολοβενζοδιαζεπινες και προϊοντα συζευξης αυτων | |
CY1120297T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων | |
CY1119960T1 (el) | Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου | |
CY1119664T1 (el) | Συνθεσεις και μεθοδοι αυξησης της μυϊκης αναπτυξης | |
CY1117319T1 (el) | Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης | |
CY1116886T1 (el) | C-met αντισωματα | |
CY1123906T1 (el) | Αναστολεις απομεθυλασης ιστονης | |
AR064458A1 (es) | Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos | |
CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
CY1116341T1 (el) | ΜΕΘΟΔΟΣ ΘΕΡΑΠΕΙΑΣ ΚΑΡΚΙΝΟΥ ΠΡΟΣΤΑΤΗ ΜΕ ΤΟΝ ΑΝΤΑΓΩΝΙΣΤΗ GnRH ΔΕΓΑΡΕΛΙΞΗ | |
CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης |